💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, fully valued.
EMCURE PHARMACEUTICALS L is scored on the pharma / healthcare framework. It keeps a healthy 10.2% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.00×). Free cash flow is worth about -0.6% of its market value.
Over the last 3 years revenue compounded at 15%/yr and profit at 19%/yr. Book value itself has compounded 23%/yr — the hallmark of a genuine compounder. Return on equity is an elite 20.5%. In the latest quarter profit grew 20% versus the prior quarter.
At 45× earnings, the stock sits at the 76th percentile of its own 2.3-year range — the expensive end of where it has historically traded. Today's price implies ~18%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 38.46 | 33.12 | worse |
| P/B | 7.86 | 8.3 | better |
| EV/EBITDA | 21.31 | 15.32 | worse |
| ROE | 20.46 | 22.94 | worse |
| ROCE | 22.81 | 24.3 | worse |
| ROA | 10.75 | 12.45 | worse |
| Quick Ratio | 0.82 | 2.09 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 15% CAGR over 3 years — steady double-digit compounder.
Profit is growing faster than revenue (19% vs 15%) — margin expansion is at work. The latest year saw a +33% swing — check if it's a one-off or structural.
Operating margin has expanded from 12% to 14% — the business is keeping more of each rupee earned.
ROE at 19% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
18% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Investing outflows exceed operating cash — the company relies on external funding to finance expansion. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 9% above earlier ones.
Profit jumped 20% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.3y median.
Promoters hold 77.8% — heavily owner-operated with strong skin in the game. MF holding up 2.2pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.